Formoterol-HFA 3-month Study in Chronic Obstructive Pulmonary Disease (COPD) Patients
Status:
Completed
Trial end date:
2006-10-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to demonstrate the clinical equivalence of formoterol-HFA pMDI
12µg/actuation administered twice daily to formoterol DPI 12µg/capsule delivered by the
Aerolizer inhaler and administered twice daily in patients with COPD.